Exploring the Intersection of Alzheimer's Disease and Vascular Factors

Saanvi Aneja

Abstract

Alzheimer's Disease (AD) and vascular risk factors have long been investigated as separate entities within the fields of neuroscience and medicine. However, emerging evidence suggests a complex connection between these two factors, leading to a need in the reevaluation of their relationship. This review implements an integrative review approach, utilizing evidence from epidemiological studies, neuroimaging, genetics, and molecular investigations. Ultimately, this paper underscores the need for a holistic understanding of AD pathogenesis that incorporates vascular factors into the disease model. Utilizing such multidisciplinary strategies paves the way to the development of novel therapeutics and therapies for AD in the future.

Introduction

Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline, memory impairment, and neuronal loss, posing a significant challenge to global health (Alzheimer's Association, 2020). Traditionally, AD has been categorized as a brain-centric disorder, focusing on the aggregation of amyloid-beta plaques and tau neurofibrillary tangles as pathological hallmarks (Hardy & Selkoe, 2002). However, recent research has revealed a more diverse picture of AD etiology—one that incorporates the influence of vascular risk factors.

Numerous evidence suggests that vascular risk factors, including hypertension, diabetes, and cerebrovascular disease, may be integral components in the development and progression of AD (Gorelick et al., 2011; Kivipelto et al., 2001; Iadecola et al., 2019). These vascular factors are known to affect the health of the brain's blood vessels, compromise cerebral blood flow, and contribute to the pathogenesis of small vessel diseases (Rensma et al., 2018). Importantly, they also share common underlying mechanisms with AD, such as inflammation, oxidative stress, and altered blood-brain barrier integrity (Iadecola et al., 2019).

This paper aims to delve into the interplay between these vascular risk factors and AD, aiming to create a more comprehensive understanding of AD pathogenesis. To achieve this, an integrative approach that synthesizes evidence from diverse research methodologies including epidemiological studies, neuroimaging techniques, genetic analyses, and molecular investigations, is utilized. Understanding the intersection of vascular risk factors and AD is not only crucial for advancing comprehension of the disease but also holds significant implications for clinical practice and therapeutic interventions. As such, this paper will not only present the

existing body of evidence but also explore the potential therapeutic avenues that may arise from this perspective.

Hypertension and Alzheimer's Disease

Emerging evidence suggests a significant association between hypertension and increased risk of AD (Xu et al., 2020). It's important to note that hypertension is both prevalent and often undertreated, making it a significant public health concern (Iadecola et al., 2019). Furthermore, hypertension is recognized as a potential modifiable risk factor for AD, raising the prospect of interventions that could mitigate AD risk (Iadecola et al., 2019).

In terms of biological mechanisms, chronic hypertension exerts profound effects on the cerebrovascular system, leading to various alterations that have implications for AD. Snyder et al. (2020) have documented that hypertension is associated with arterial stiffness, making blood vessels less flexible and impairing cerebral autoregulation, or the intrinsic ability of the brain to maintain blood flow at a nearly constant rate. These alterations collectively contribute to compromised cerebral blood flow regulation and small blood vessel damage in the brain, with potential repercussions for cognitive function (Iadecola et al., 2019).

Additionally, molecular investigations have shed light on the methods through which hypertension may contribute to AD pathology. Notably, Ladecola and colleagues (2019) have hypothesized that chronic hypertension may lead to increased production of amyloid-beta, a hallmark protein in AD pathogenesis. Moreover, hypertension has been associated with alterations in tau protein phosphorylation, a key player in the formation of neurofibrillary tangles, another pathological hallmark of AD (Iadecola et al., 2019). These molecular insights underscore the intricate relationship between hypertension and AD, suggesting potential targets for therapeutic intervention.

Diabetes and Alzheimer's Disease

Epidemiological studies have consistently shown an association between diabetes and an elevated risk of AD, implying a potential link between metabolic dysfunction and neurodegenerative processes (Biessels et al., 2014).

The overlapping of impaired insulin signaling pathways in both diabetes and AD is an important aspect to consider (Biessels et al., 2014). Dysregulated insulin signaling, a clear feature of diabetes, has been implicated in the pathogenesis of AD. Dysfunctions in insulin signaling can

contribute to amyloid-beta accumulation, a defining characteristic of AD, as well as tau hyperphosphorylation, another key facet of AD pathology as mentioned before.

Another intriguing link between diabetes and AD lies in the formation of advanced glycation end products (AGEs) through glycation processes (Sasaki et al., 2018). AGEs have been identified in both conditions, suggesting a shared pathogenic pathway. AGEs may play a crucial role in linking diabetes and AD by contributing to neuroinflammation and oxidative stress. These processes can lead to neuronal damage and may serve as a unifying factor in the development and progression of both conditions. Exploring the role of AGEs in diabetes-AD crosstalk provides a promising avenue for uncovering potential therapeutic targets.

Cerebrovascular Disease and Alzheimer's Disease

Cerebrovascular disease refers to a group of conditions that affect blood flow and the blood vessels in the brain. Small vessel disease specifically is increasingly acknowledged as a precursor to AD (Rensma et al., 2018). This recognition is made due to pathological evidence that reveals that cerebrovascular pathology co-occurs with AD neuropathology.

For instance, chronic cerebral hypoperfusion is commonly associated with Cerebrovascular Disease and has been closely associated with cognitive impairment and AD-related changes (Iadecola et al., 2019). This association underscores the potential mechanistic link between vascular factors and the progression of AD. Chronic reductions in cerebral blood flow can lead to hypoxic, or low oxygen, conditions, resulting in neuronal damage and cognitive decline.

Potential Therapeutic Mechanisms

Inflammatory Responses:

Inflammatory responses represent a pivotal connection between vascular risk factors and AD pathogenesis. Chronic neuroinflammation is a prevailing feature observed in both vascular and AD-related pathologies (Iadecola et al., 2019). The convergence of inflammatory cascades depicts the intricate interplay between these conditions. Identifying the specific mediators and mechanisms that drive inflammation in the context of vascular risk factors and AD is imperative for uncovering potential therapeutic targets aimed at mitigating neuroinflammation and its detrimental effects.

Oxidative Stress and Mitochondrial Dysfunction:

Oxidative stress and mitochondrial dysfunction emerge as shared pathways in the realms of vascular risk factors and AD (Chen et al., 2020). These mechanisms have the potential to inflict

significant neuronal damage and contribute to the progression of both conditions. Oxidative stress-induced neuronal injury and mitochondrial impairment are intricately linked to neurodegenerative processes. Exploring interventions that can improve oxidative stress and enhance mitochondrial function may offer promising therapeutic strategies for addressing the complex interplay between vascular risk factors and AD.

Biomarkers for Vascular-AD Subtypes:

In terms of biomarkers, a promising avenue for improving understanding the connection between vascular risk factors and AD is the emergence of novel markers, particularly neuroimaging-based indicators of vascular pathology (Vemuri et al., 2020). These evolving biomarkers hold the potential to distinguish distinct vascular-AD subtypes, a development that could significantly enhance early diagnosis and personalized treatment strategies. The identification and validation of such biomarkers may lead to more precise clinical interventions and improved patient outcomes.

Conclusion

The above review shows a strong relationship between vascular risk factors and Alzheimer's disease (AD). The synthesis of evidence from epidemiological studies, neuroimaging, genetics, and molecular investigations reveals a complex interplay that extends beyond the traditional view of AD as solely a neurodegenerative disorder. Therefore, future research endeavors should focus on multidisciplinary strategies aimed at further exploring this intricate interaction in order to deepen comprehension of AD etiology and offer potential avenues for prevention and treatment. Additionally, the identification of robust biomarkers that are capable of distinguishing vascular-AD subtypes should remain a priority, as early diagnosis and personalized interventions may hold significant promise for enhancing patient outcomes in the battle against AD.

References

1. Alzheimer's Association. (2020). Alzheimer's disease facts and figures. Alzheimer's & Dementia, 16(3), 391-460.

2. Biessels, G. J., Strachan, M. W., Visseren, F. L., Kappelle, L. J., & Whitmer, R. A. (2014). Dementia and cognitive decline in type 2 diabetes and prediabetic stages: Towards targeted interventions. The Lancet Diabetes & Endocrinology, 2(3), 246-255.

3. Chen, X., Guo, C., Kong, J., Oxenkrug, G., & Cui, Q. (2020). The interaction between mitochondrial dysfunction and inflammation in Alzheimer's disease. Frontiers in Aging Neuroscience, 12, 188.

4. Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., ... & Schneider, J. A. (2011). Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 42(9), 2672-2713.

5. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353-356.

6. Kivipelto, M., Helkala, E. L., Hänninen, T., Laakso, M. P., Hallikainen, M., Alhainen, K., ... & Nissinen, A. (2001). Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology, 56(12), 1683-1689.

7. Ladecola, C., Gottesman, R. F., & Moskowitz, M. A. (2019). Hypertension and dementia. Hypertension, 74(2), 171-179.

8. Rensma, S. P., van Sloten, T. T., Launer, L. J., Stehouwer, C. D., & Cordonnier, C. (2018). Cerebral small vessel disease and risk of incident stroke, dementia, and depression, and all-cause mortality: A systematic review and meta-analysis. Neurology, 91(8), e832-e842.

9. Power MC, Weuve J, Gagne JJ, McQueen MB, Viswanathan A, Blacker D. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology. 2011 Sep;22(5):646-59. doi: 10.1097/EDE.0b013e31822708b5. PMID: 21705906; PMCID: PMC3640480.

10. Sasaki, N., Fukatsu, R., Tsuzuki, K., Hayashi, Y., Yoshida, T., Fujii, N., & Koike, T. (2018). Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. The American Journal of Pathology, 153(4), 1149-1155.

11. Snyder HM, Asthana S, Bain L, Brinton R, Craft S, Dubal DB, Espeland MA, Gatz M, Mielke MM, Raber J, Rapp PR, Yaffe K, Carrillo MC. Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. Alzheimers Dement. 2016 Nov;12(11):1186-1196. doi: 10.1016/j.jalz.2016.08.004. Epub 2016 Sep 27. PMID: 27692800; PMCID: PMC10341380.

12. Vemuri, P., Lesnick, T. G., Przybelski, S. A., Graff-Radford, J., Reid, R. I., Lowe, V. J., ... & Jack Jr, C. R. (2020). Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 88(3), 434-449.